poisar

Stocks · News reference

Orchestra BioMed Reports Third Quarter 2026 Financial Results and Business Updates

Fiscal.ai

Orchestra BioMed announced its third-quarter 2026 financial results, highlighted the completion of enrollment for its BACKBEAT pivotal trial, and confirmed a cash runway extending through 2028.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Orchestra BioMed Holdings, Inc. (OBIO)

    Filed: 2026-11-09 AccNo: 0001104659-26-124502 Size: 587 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

  2. Globenewswire IncNa

    Orchestra BioMed Announces Pricing of Public Offering

    Orchestra BioMed (OBIO) announced the pricing of an underwritten public offering of 15 million shares at $5.00 per share, expected to raise $75 million in gross proceeds. The company plans to use the funds to advance its AVIM Therapy program and BACKBEAT clinical trial for hypertension treatment, as well as its Virtue SAB program for coronary in-stent restenosis, alongside other research and development initiatives.